NEW YORK (TheStreet) -- Radius Health (RDUS) shares are up 18.65% to $61.38 on Thursday on heavy market trading after the biopharmaceutical company announced that top-line data from its ACTIVE and ACTIVExtend trials have met the primary and secondary endpoints necessary for a new drug application submission.
ACTIVE and ACTIVExtend are its osteoporotic fracture treatment candidates.
Osteoperosis is a degenerative bone disease that afflicts about 200 million people worldwide and causes about 9 million fractures annually, according to the International Osteoporosis Foundation.
The company released data from the first six months of the ACTIVExtend trial as well as the 25-month combined data from the ACTIVE and ACTIVExtend tiral.
"We are extremely pleased with the consistency of the positive results of both the ACTIVE and ACTIVExtend trials, which support the potential use of abaloparatide for the treatment of postmenopausal osteoporosis. We are excited about continuing our active dialogue with health authorities as we prepare our regulatory submissions," said CEO Robert E. Ward.